Lisata is showing encouraging early results for its lead cancer drug, and new partnerships plus long-lasting patent protection could widen the set of cancers it can treat and help it compete if the drug reaches patients. The catch is it still burns cash, relies heavily on raising more money, and may struggle to launch and sell a medicine at scale if later trials or regulators don’t go its way.Read more
Key Takeaways Breakthrough potential in solid tumor therapies and extended exclusivity position the company for long-term, high-margin growth with minimal generic competition. AI-driven innovation, strategic partnerships, and a strong pipeline in oncology are set to diversify revenue streams and enhance profitability.Read more
Catalysts About Lisata Therapeutics Lisata Therapeutics is a clinical stage biotech company focused on developing certepetide as a tumor targeting agent in combination with existing cancer therapies. What are the underlying business or industry changes driving this perspective?Read more
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
